Evidence map›Paper›PMID 39647571›Full record

ReviewEuropean journal of pharmacology2025

Sex differences in gut microbiota, hypertension, and cardiovascular risk.

Anish Sharma, Sahil Kapur, Priyal Kancharla, Tao Yang

Abstract readReview
In one paragraph

Review in European journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Gut microbiota's role in heart failure.Heart failure reviews · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anish SharmaCenter for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA.
Sahil KapurCenter for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA.
Priyal KancharlaCenter for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA.
Tao YangCenter for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA. Electronic address: Tao.yang2@utoledo.edu.

Funding

Role of gut commensal Coprococcus comes in angiotensin-converting enzyme inhibitor resistant hypertensionR21AG079357 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI YANG, TAO · 2022 to 2023
$425k
American Heart Association-American Stroke Association 852969NIA NIH HHS R21 AG079357
6 · The paper itself

Abstract

The intricate ecosystem of the gut microbiome exhibits sex-specific differences, influencing the susceptibility to cardiovascular diseases (CVD). Imbalance within the gut microbiome compromises the gut barrier, activates inflammatory pathways, and alters the production of metabolites, all of which initiate chronic diseases including CVD. In particular, the interplay between lifestyle choices, hormonal changes, and metabolic byproducts uniquely affects sex-specific gut microbiomes, potentially shaping the risk profiles for hypertension and CVD differently in men and women. Understanding the gut microbiome's role in CVD risk offers informative reasoning behind the importance of developing tailored preventative strategies based on sex-specific differences in CVD risk. Furthermore, insight into the differential impact of social determinants and biological factors on CVD susceptibility emphasizes the necessity for more nuanced approaches. This review also outlines specific dietary interventions that may enhance gut microbiome health, offering a glimpse into potential therapeutic avenues for reducing CVD risk that require greater awareness. Imbalance in natural gut microbiomes may explain etiologies of chronic diseases; we advocate for future application to alter the gut microbiome as possible treatment of the aforementioned diseases. This review mentions the idea of altering the gut microbiome through interventions such as fecal microbiota transplantation (FMT), a major application of microbiome-based therapy that is first-line for Clostridium difficile infections and patient-specific probiotics highlights more innovative approaches to hypertension and CVD prevention. Through increased analysis of gut microbiota compositions along with patient-centric probiotics and microbiome transfers, this review advocates for future preventative strategies for hypertension.

Indexed as

Cardiovascular DiseasesGastrointestinal MicrobiomeHypertensionSex CharacteristicsAnimalsFecal Microbiota TransplantationFemaleHeart Disease Risk FactorsHumansMaleProbioticsSex FactorsDysbiosisFecal microbiota transplantation (FMT) cardiovascular diseases (CVD)Gut microbiomeHypertensionInflammationProbioticsSex differences

Identifiers

PMID39647571
PMCPMC11714433

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.